ALNOV Share Price Performance
€0.46
-0.28 (-37.65%)
Price €0.46
Share Price€0.46
We're Not Very Worried About Novacyt's (EPA:ALNOV) Cash Burn Rate
Aug 14
Novacyt S.A. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
ALNOV Community Narratives
There are no narratives available yet.
Novacyt S.A. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.40
- Gross Margin
- 57.70%
- Net Profit Margin
- -146.48%
- Debt/Equity Ratio
- 0%
Novacyt S.A. Competitors
Snowflake Analysis
About ALNOV
- Founded
- 2006
- Employees
- 234
- CEO
- WebsiteView website
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. It operates in the United Kingdom, France, Europe, the United States, the Asia Pacific, the Middle East, and Africa. The company was incorporated in 2006 and is based in Le Vésinet, France.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
French Market Performance
- 7 Days: 0.9%
- 3 Months: 1.7%
- 1 Year: 3.2%
- Year to Date: 5.7%
Over the last 7 days, the market has remained flat, although notably the Healthcare sector gained 4.7% in that time. As for the longer term, the market has risen 3.2% in the past 12 months. Looking forward, earnings are forecast to grow by 12% annually. Market details ›